Sociedad Americana de Hirudoterapia

Distinct 3-disulfide-bonded isomers of tridegin differentially inhibit coagulation factor XIIIa

Structural biology published in European Journal of Medicinal Chemistry (2020)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Desarrollo de fármacosFarmacología salivalBäuml CA et al. · European journal of medicinal chemistry, 2020

Abstract

Tridegin is a 66mer cysteine-rich coagulation factor XIIIa (FXI-IIa) inhibitor from the giant amazon leech Haementeria ghilianii of yet unknown disulfide connectivity. This study covers the structural and functional characterization of five different 3-disulfide-bonded tridegin isomers. In addition to three previously identified isomers, one isomer containing the inhibitory cystine knot (ICK, knottin) motif, and one isomer with the leech antihemostatic protein (LAP) motif were synthesized in a regioselective manner. A fluorogenic enzyme activity assay revealed a positive correlation between the constriction of conformational flexibility in the N-terminal part of the peptide and the inhibitory potential towards FXI-IIa with clear differences between the isomers. This observation was supported by molecular dynamics (MD) simulations and subsequent molecular docking studies. The presented results provide detailed structure-activity relationship studies of different tridegin disulfide isomers towards FXI-IIa and reveal insights into the possibly existing native linkage compared to non-native disulfide tridegin species.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAmino Acid SequenceAnimalsDisulfidesFactor XIIIaGenesIsomerismLeechesMolecular Docking SimulationMolecular Dynamics SimulationProtein BindingProtein ConformationSalivary Proteins and Peptides

Resumen

Characterizes 3-disulfide-bonded isomers of leech-derived tridegin, a Factor XIIIa inhibitor — defines structure-activity for clot-stabilization inhibitor.

Por qué esto importa para la hirudoterapia

This study characterized five different three-disulfide-bonded isomers of tridegin, a 66-mer factor XIIIa (FXIIIa) inhibitor from the giant Amazon leech Haementeria ghilianii, finding that conformational flexibility in the N-terminal region correlated with inhibitory potency, supported by molecular dynamics and docking studies. For ASH's domain, this is directly relevant as a structure-activity study of a leech-derived anticoagulant peptide targeting FXIIIa. However, the work is entirely structural/computational (synthetic peptides, enzyme assays, modeling) with no animal or human data, and the native disulfide connectivity remains unresolved. It is preliminary medicinal chemistry rather than a therapy study.

Citación

Distinct 3-disulfide-bonded isomers of tridegin differentially inhibit coagulation factor XIIIa.

Bäuml CA et al. · European journal of medicinal chemistry, 2020

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.